X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
oncology (9) 9
cancer (7) 7
index medicus (7) 7
aged (6) 6
female (6) 6
male (6) 6
metastasis (6) 6
middle aged (6) 6
survival (6) 6
adult (5) 5
analysis (5) 5
chemotherapy (5) 5
hematology, oncology and palliative medicine (5) 5
colorectal cancer (4) 4
disease-free survival (4) 4
expression (4) 4
mutation (4) 4
neuroblastoma (4) 4
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cetuximab (3) 3
genomics (3) 3
multivariate analysis (3) 3
oncology, experimental (3) 3
oxaliplatin (3) 3
research (3) 3
treatment outcome (3) 3
tumors (3) 3
adolescent (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
animals (2) 2
antibodies (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal, humanized (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bevacizumab (2) 2
bevacizumab - therapeutic use (2) 2
biology (2) 2
biomarkers, tumor - genetics (2) 2
calcium (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
cancer patients (2) 2
care and treatment (2) 2
cell (2) 2
cell line, tumor (2) 2
child (2) 2
child, preschool (2) 2
colorectal neoplasms - drug therapy (2) 2
colorectal neoplasms - genetics (2) 2
colorectal neoplasms - pathology (2) 2
combination (2) 2
confidence intervals (2) 2
extracellular matrix (2) 2
fluorouracil - administration & dosage (2) 2
gene expression (2) 2
genetic aspects (2) 2
infant (2) 2
kaplan-meier estimate (2) 2
kras (2) 2
leucovorin - administration & dosage (2) 2
liver (2) 2
loss of heterozygosity (2) 2
medulloblastoma (2) 2
medulloblastoma - genetics (2) 2
metastases (2) 2
metastatic colorectal cancer (2) 2
mutations (2) 2
organoplatinum compounds - administration & dosage (2) 2
patient outcomes (2) 2
patients (2) 2
prognosis (2) 2
proportional hazards models (2) 2
proteins (2) 2
proto-oncogene proteins b-raf - genetics (2) 2
resection (2) 2
retrospective studies (2) 2
survival analysis (2) 2
therapy (2) 2
trial (2) 2
12p (1) 1
1st-line treatment (1) 1
2p (1) 1
3d scaffolds (1) 1
activation (1) 1
acute-phase response (1) 1
adenocarcinoma (1) 1
adrenal gland neoplasms - mortality (1) 1
adrenal gland neoplasms - secondary (1) 1
adrenal gland neoplasms - surgery (1) 1
adrenal metastasis (1) 1
aged, 80 and over (1) 1
aminobisphosphonate derivative (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
angiogenesis inhibitors - adverse effects (1) 1
anti-inflammatory agents - chemistry (1) 1
anti-inflammatory agents - pharmacology (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 8, pp. 753 - 762
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents
Journal Article
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 73, pp. 74 - 84
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 04/2013, Volume 14, Issue 4, pp. 7492 - 7505
Journal Article
Cell Cycle, ISSN 1538-4101, 02/2012, Volume 11, Issue 3, pp. 569 - 581
Journal Article
Cancer Letters, ISSN 0304-3835, 2011, Volume 308, Issue 2, pp. 215 - 224
Journal Article